U.S. Markets closed

CNS Pharmaceuticals, Inc. (CNSP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.9950-0.0750 (-7.01%)
At close: 04:00PM EST
0.9600 -0.04 (-3.52%)
After hours: 06:32PM EST

CNS Pharmaceuticals, Inc.

2100 West Loop South
Suite 900
Houston, TX 77027
United States
800 946 9185

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Mr. John Michael Climaco Esq., J.D.Chairman, CEO & Pres635.1kN/A1969
Mr. Christopher S. Downs CPA, CTP, FP&AChief Financial Officer394.7kN/A1979
Dr. Sandra L. SilbermanChief Medical Officer213.9kN/A1956
Dr. Waldemar Priebe Ph.D.Founder & Chairman of the Scientific Advisory BoardN/AN/AN/A
Dr. Donald H. PickerChief Science OfficerN/AN/A1946
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was founded in 2017 and is based in Houston, Texas.

Corporate Governance

CNS Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.